Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / SKYE - Skye Bioscience to Host Virtual KOL Event Metabolic Rewiring with CB1 Inhibition on July 24th | Benzinga


SKYE - Skye Bioscience to Host Virtual KOL Event Metabolic Rewiring with CB1 Inhibition on July 24th | Benzinga

  • SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will host a virtual KOL event entitled "Metabolic Rewiring with CB1 Inhibition" on Wednesday, July 24, 2024, at 9:00 AM ET.

    The KOL event will feature Louis J. Aronne, MD, FACP (Weill Cornell Medicine), Marcus DaSilva Goncalves, MD, PhD (NYU Langone Health), Lee M. Kaplan, MD, PhD (Geisel School of Medicine at Dartmouth), and Beverly Tchang, MD (Weill Cornell Medicine), who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism.

    The event will focus on the scientific rationale for Skye's Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024.

    A question and answer session will follow the formal presentations.

    Advanced registration is required to participate in the webcast and can be completed by clicking here. For those unable to listen live, a replay of the call will be available.

    If you would like to submit a question for the Q&A session, please email:
    questions@lifesciadvisors.com

    KOL Biographies:

    Louis Aronne, MD, a leading authority on the treatment of obesity, is the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College. He directs the Center for Weight Management and Metabolic Clinical Research and is an adjunct appointment at Columbia University College of Physicians and Surgeons. Dr. Aronne is Founder and CEO of BMIQ, a weight control program. He has authored over 60 papers and book chapters on obesity and edited the National Institutes of Health Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Skye Bioscience Inc Com
    Stock Symbol: SKYE
    Market: OTC
    Website: skyebioscience.com

    Menu

    SKYE SKYE Quote SKYE Short SKYE News SKYE Articles SKYE Message Board
    Get SKYE Alerts

    News, Short Squeeze, Breakout and More Instantly...